2008 Executive Leadership Conference 2008 Executive Leadership Conference “Challenge, Performance,...

2008 Executive Leadership Conference

2008 Executive Leadership Conference“Challenge, Performance, and Accountability”

Program TrackWelcome and Introductions

Gigi PolitoskiSenior VP for Programs


About the NKF Program Department

Five Business AreasGigi Politoski

Senior Vice President for Programs

Holly DeVan Managing Director Kidney Learning System

Tracy Fortson Managing

Director Constituent

Services

Dawn Townsend Program Director

US Transplant Games

Anthony Gucciardo Vice

President for Corporate Relations

Monica GannonEarly Intervention Programs

Director


• Over 40 program staff in New York City

• Program staff in Kansas City, Philadelphia, St. Louis, Minneapolis, Greater New York, and Upstate New York

• Nurses, dietitians, social workers, science writers, adult educators, public relations and marketing

About the NKF Program Department


• Establishing People Like US (PLU)• Transforming our patient

constituency into and active force within NKF and throughout the country

• Putting a patient face on the organization and everything it does

NKF’s Strategic PlanGoals that Focus on Program:

1. To Empower Patients and Their Families


NKF’s Strategic PlanGoals that Focus on

Program:

• Building on the impact of KDOQI and KEEP• Addressing Risk Factors like diabetes and

hypertension• Pursuing the knowledge that CKD is a

multiplier of risk, cost and poor outcomes• Utilizing new strategies, targeting new

audiences, and interacting on a higher level with public health and treatment communities

2. To Increase Identification of, and Improve Treatment for Those With or at Risk of Kidney Disease


NKF’s Strategic PlanGoals that Focus on

Program:

• Focus on the late or “no” referral of our patients to transplantation

• Increase living donation and concepts like Paired Exchange

• Focus more on the “transition” of our patients from Stages 3 to 4 and then from Stages 4 to 5

• Ensure that transplant recipients keep the transplant they have

3. To Improve Patient Care Through Early Transplantation


Program Track Agenda

• Cardio Kidney Diabetes or the “New CKD”• Empowering Patients and Their Families

*Session with CEOs and a Train the Trainer session for program staff

• Listening to our Constituents*Highlights of NKF needs

assessment and market research• Hot topics in transplantation including

the upcoming U.S. Transplant Games• Program Round Tables featuring some

“best practices”


Cardio Kidney Diabetes The Triple Threat: Working

with New Opportunities

Gigi Politoski, SVP for ProgramsHolly DeVan, Managing Director, KLS

Ellen Yoshiuchi, Program Director, Greater New York

Anthony Gucciardo, VP Corporate Relations


Expanding NKF’s Programs: Scope and Reach

The Challenges:• 26 million people have CKD, another

20 million are at risk• Not aware, not identified, not

treated• Not seen by a nephrologist• Patients and their physicians have

no real connection with NKF


Expanding NKF’s Programs: Scope and Reach

The Opportunities: • Finds and attracts new patient and

professional constituents• Allows NKF to move into a new space, a

bigger space, and across other disease states

• Expands NKF’s message and builds more brand equity for NKF

• Serves as a catalyst for new programs based on new constituent needs

• Attracts new corporate partners

Saves Lives


Distribution of Medicare Patients & Costs

CKD represents 6% of Medicare enrollees and they account for 18% of the expenditures


Distribution of EGHP Patients & Costs:

CKD represents 1% of the population age 50-64 and account for 9% of the expenditures in EGHPs


CKD is a Risk and Cost Multiplier

CKD subpopulation is very expensive and has high event rates, making it a major public health issue


Cardiovascular – Kidney – Diabetes

Core Messages• Cardiovascular disease is the number one

killer of people with CKD

• Chronic Kidney Disease multiplies CVD risk

• For every CVD risk factor (Diabetes, Hypertension, Dyslipidemia, Anemia), clinicians must test for CKD


Cardiovascular – Kidney – Diabetes

Core Messages• CKD is the disease multiplier:

1. The patients are sicker 2. Risk factor levels are higher3. Control is worse and treatment is more

complex4. Outcomes are worse5. Costs are higher

• MDs don’t need to find new patients • With CKD, patient management is different• Treatments are available and effective today


NKF’s Message in Stage 4 CKD

Stage 4 CKD is an asymptomatic clinical event!

It’s a “Kidney Attack”• We can slow progression in Stage 4• We can reduce the incidence of bad events that

occur in Stage 4• We can reduce the severity of Stage 4 co-

morbidities• We can improve the coordination of care in Stage 4 • We can prevent:

– Cardiovascular events– Death


Launching The New CKD Paradigm

• NKF, the authoritative voice on CKD pulls disease states together

• Global KDOQI conference October, 2007– George Bakris, MD (Nephrology)– Mark Molitch, MD (Diabetes)– Richard Nesto, MD (Cardiology)

• 80 key opinion leaders including primary care and family practice MDs

• 2 ½ days


Goals• Investigate and understand the

relationship between CVD, diabetes and CKD

• Explore the impact of CKD as a disease multiplier

• Discuss barriers to optimal care (early identification, diagnosis of co-morbid conditions, specialist care/primary care)

• Evaluate available treatment options • Provide recommendations on what you

do with what we know


Cardio Kidney Diabetes (CKD) Conference

• Chairs: George Bakris, Mark Molitch, Richard Nesto• By invitation-only: Nephrology, Cardiology,

Endocrinology, Epidemiology, Primary Care community leaders

• Goal: to identify practical approaches to early identification and management of risk factors in:* Cardiovascular disease* Chronic kidney disease, and/or * Diabetes

• Need for collaboration between specialties to improve care of patients with overlapping disease processes.

October 2007 in Chicago


Cardio Kidney Diabetes (CKD) Conference

• Recommendations about:* Influence of Blood Pressure Targets on Vascular

Injury in Chronic Kidney Disease* Impact of Dyslipidemia Management on

Atherosclerosis* Progression in Chronic Kidney Disease

* Impact of Glycemic Control on Vascular Injury in Chronic Kidney Disease

* Clinical Implications for Interactions of Chronic Kidney Disease on Vascular Injury

• Recommendations are being developed for multiple publications

• Cross-disciplinary to reach audiences from all 3 disease states and family practice


Cardio-Kidney-Diabetes Challenge Growth for KLS

and for YouMeeting the Challenge Through Educational Programs and Resources!


What is the Kidney Learning System?

•Team of 18 Medical, Education, Marketing Specialists in NY•Research, Develop, Deliver and Publish, Promote Educational Tools and Resources•Traditional Formats and new technology-based delivery of learning such as interactive online tools, web casts, software and Palm/Pocket PCs•Collaborations with multi-media education distributors such as Medscape and Epocrates•Every project is funded through an educational grant


• Patient and Public Education • KDOQI Guideline Implementation:

Caddies/Tools• Formal “CME/CE” Professional

Activities– Over 12,000 Learners in 2007

• Clinician Education, Resources and Tools

Try to have a patient component in all professional activities

Areas of Focus


Program Development

Pilot Testing

and Evaluation

Concept

KDOQI KDIGO

Guidelines and Latest

Science

Patients, Physicians, Clinicians

Delivery in variety of formats

Needs Assessment

Outcomes

Recruitment of content experts

Programs

Rigorous KLS Development Process


KLS Programs in Diverse Formats and Media

• CME/CE – Live meetings– Teleconferences– Printed monographs– Online monographs– CD-ROMs – E-Learning and Web

Offerings• Books/Primers• Wall Charts• Pocket Tools• VHS Videos/DVDs• CD-ROMs

• Audio/Video/Internet Conferences

• Online Interactive Software

• PDA Software • Pocket PC Software• Co-Sponsored

Meetings & Symposia• Teaching

Brochures/Manuals• NKF-Hosted Courses• Train-the-Trainer


Cardio-Kidney-Diabetes Challenge Growth for KLS

and for YouNew Target Audiences for Educational

Opportunities

PCP, IM, Family Practitioners, ER Women’s Health

Specialists: Cardiologists, Endocrinologists, Surgeons HIV and Infectious Disease

Doctors of OsteopathyPhysician Assistants

PharmacistsNurse PractitionersDiabetes Educators

Community Employers: Benefits and Wellness ExecutivesState and Local Healthcare Executives


These are YOUR Patients, You are Treating Them Already!!

WHO: Diabetes, High Blood Pressure, Cardiovascular DiseaseWHAT: Find the CKDHOW: 3 Simple Tests

(Protein in Urine, Blood Pressure, GFR)CONTENT: Co Morbidities and Complications Progression

Multi-disciplinary approach to Treatment

Cardio-Kidney-Diabetes ChallengeNew Messages and Content


Cardio-Kidney-Diabetes Challenge Growth for KLS and

for YouHow to Tackle the CKD Challenge for your Professional Audiences

Build Your Network Through Team Teaching• Your Nephrologists and PCP• Your Nurses/Dietitians and Diabetes Educators

and NPs

Leverage Your KEEP Opportunities and KEEP Physicians

Expand Your Topics: KLS and KDOQI Resources– New KDOQI Diabetes Guidelines– KDOQI Hypertension and Lipids Guidelines– CKD Conference Articles– The Kidney Disease Story– FREE KLS CME/CE Programs!


Cardio-Kidney-Diabetes Challenge

Growth for KLS and for YouLeverage KLS

Resources • CME/CE Programs on

CKD Risk Reduction and CoMorbidities to Distribute to your volunteers, board members, community clinicians

• Online at KLS Website

• Tahan Engram x 299• Crystal Tucker x 175

for bulk orders


A Program for CKD Risk Identification and Reduction – Affiliate Central


The Kidney Disease Story

• A fully scripted learning activity for live presentations in the community

• Developed to help NKF Affiliate outreach and visibility to:– People at increased risk for CKD – People recently diagnosed with CKD– Lay public/Community groups/Senior organizations– Health educators– General audiences


The Kidney Disease Story

• Includes:– A 45 to 60-minute scripted slide presentation– Down-loadable:

• Pre & post self-assessment to help measure participant learning and benefit

• “Are You at Risk?” participant checklist handout • Program evaluation to gauge participant

satisfaction• Speaker notes



Growth for KLS and for You Building Professional

Programs• Partner with Local Hospitals for “Grand Rounds” Programs on CKD

• Reach out to State and Local Agencies for Funding, i.e. Diabetes Coalitions

• Use Technology to Deliver Your Programs– Roundtable: Using Teleconferencing to Reach

Remote and Rural Locations• Expand your Annual Meeting and

Specialty Programs • Partner with KLS to deliver CME/CE

Programs locally, i.e. PCP – KEEP Risk Reduction



Growth for KLS and for You Building Professional

Programs• Continuing Education Programs

(CME/CE)• Rigorous ACCME Regulations• Accountable to Nurses, NP,

Pharmacists associations• Continue using your Local Provider • Divisions Contact: Bina George, x

115 KLS



Greater New York Case Study


Broadening the Fundraising Net

Anthony GucciardoVice President, Corporate

Relations


ESKD is the Tip of the Iceberg in the realm of CKD


26 Million U.S. Adults CKD stage N

Stage 5 350,000

Stage 4 700,000

Stage 3 15.5 million

Stage 2 6.5 million

Stage 1 3.6 Million


CKD is the Tip of Cardio-Kidney-Diabetes Iceberg


CKD + Major Risk Factors

CKD (All Stages)

Diabetes

Cardiovascular Disease


122236

Pharmaceutical Companies with CKD Specific Therapeutics including Transplant

Pharmaceutical Companies with CKD Specific Therapeutics including Transplant and Diabetes

Pharmaceutical Companies with CKD Specific Therapeutics including Transplant and Diabetesand Cardiovascular Disease

• Abbott• American

Regent• Amgen• Fresenius • Genzyme• Ortho • Shire• Watson

• Astellas• Novarti

s• Roche• Wyeth

Total =

• Amylin• Bayer• BMS• GlaxoSmithKlin

e• Merck• NovoNordisk• Novartis• Pfizer• Sanofi-Aventis• Takeda

• Abbott• Astrazeneca• BI• BMS• CV Therappeutics• Daiichi Sankyo• Forest Laboratories• GlaxoSmithKline• King• Merck• Novartis• Pfizer• Reliant

Pharmaceuticals• Sanofi-Aventis

Pharmaceutical Companies with CKD Specific Therapeutics

8


Successful Pharma fund-raising is not magic,

and nothing is a given...

It’s very hard work!

• It is planning, executing, and assessing.

• It is knowing your organization and what it needs.

• It is knowing your potential funders.

• Results Accountability!


"So it would be better to approach you about your

annual donation in the spring?“THE CHRONICLE OF PHILANTHROPY J.P. RINI


Challenges Raising Pharma $ in 2008

• Hard times for many pharmaceutical companies... less sales = less $

• Competition... More people going after less $

• No more local budgets



• Online grant submissions = less personal interaction

• All online grant applications are different = time consuming and confusing

• Each company’s regulations are different = time consuming and confusing



• Be careful to avoid red flags... Watch your terminology (words like referral)

• Be sure to include Measurable Outcomes

• Program Sustainability• Consider Multi-sponsorship


Key to Funding Longevity…

Diversification!!!


Potential Funding Sources

• Trustees Of The Organization (Board Members)

• Individuals • Corporations (Pharma and Non-Pharma)• Private Foundations • Community Foundations • Government• Internet

All of the Above!!!


Join Me at the Programs Roundtables Tomorrow for:

10 Essentials for Writing a Grant Request Proposal

Date post:	26-Dec-2015
Category:	Documents
Upload:	sandra-welch
View:	217 times
Download:	2 times

2008 Executive Leadership Conference 2008 Executive Leadership Conference “Challenge, Performance,...

Documents